Concepts (182)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 20 | 2023 | 1198 | 2.460 |
Why?
|
| Insulin Resistance | 2 | 2022 | 412 | 0.620 |
Why?
|
| Biopsy, Needle | 3 | 2002 | 138 | 0.460 |
Why?
|
| Mammary Glands, Human | 4 | 2019 | 56 | 0.440 |
Why?
|
| Breast | 4 | 2007 | 183 | 0.430 |
Why?
|
| Physician Incentive Plans | 1 | 2013 | 9 | 0.420 |
Why?
|
| Weight Gain | 2 | 2022 | 169 | 0.420 |
Why?
|
| Medical Oncology | 1 | 2013 | 66 | 0.400 |
Why?
|
| Hematologic Neoplasms | 1 | 2013 | 49 | 0.400 |
Why?
|
| Quality of Health Care | 1 | 2013 | 519 | 0.310 |
Why?
|
| Female | 22 | 2023 | 32880 | 0.280 |
Why?
|
| Mastectomy | 3 | 2022 | 58 | 0.270 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2023 | 89 | 0.260 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2005 | 46 | 0.230 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2004 | 32 | 0.220 |
Why?
|
| Humans | 25 | 2023 | 63445 | 0.220 |
Why?
|
| Carcinoma, Lobular | 1 | 2004 | 26 | 0.220 |
Why?
|
| Carcinoma in Situ | 1 | 2004 | 35 | 0.210 |
Why?
|
| Neoplasms, Second Primary | 1 | 2004 | 49 | 0.210 |
Why?
|
| Intraoperative Period | 1 | 2003 | 33 | 0.200 |
Why?
|
| Estrogens | 2 | 2023 | 116 | 0.200 |
Why?
|
| Postmenopause | 2 | 2023 | 237 | 0.190 |
Why?
|
| Body Mass Index | 2 | 2022 | 867 | 0.190 |
Why?
|
| Neoadjuvant Therapy | 1 | 2023 | 87 | 0.190 |
Why?
|
| Biopsy | 2 | 2007 | 443 | 0.190 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2022 | 15 | 0.190 |
Why?
|
| Middle Aged | 14 | 2023 | 17613 | 0.190 |
Why?
|
| Polychlorinated Biphenyls | 1 | 2022 | 40 | 0.190 |
Why?
|
| Papilloma | 1 | 2002 | 12 | 0.190 |
Why?
|
| Mastectomy, Segmental | 1 | 2022 | 46 | 0.180 |
Why?
|
| Insulin | 2 | 2022 | 686 | 0.170 |
Why?
|
| Patient Care Team | 1 | 2023 | 338 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 345 | 0.160 |
Why?
|
| Mammography | 1 | 2022 | 281 | 0.160 |
Why?
|
| Biomarkers, Tumor | 2 | 2020 | 507 | 0.160 |
Why?
|
| Receptors, Estrogen | 1 | 2020 | 128 | 0.150 |
Why?
|
| Epithelial Cells | 2 | 2022 | 390 | 0.150 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2019 | 152 | 0.140 |
Why?
|
| Cancer Survivors | 1 | 2020 | 116 | 0.140 |
Why?
|
| Prospective Studies | 2 | 2022 | 3293 | 0.140 |
Why?
|
| Benzhydryl Compounds | 1 | 2018 | 51 | 0.140 |
Why?
|
| Phenols | 1 | 2018 | 78 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 525 | 0.130 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2017 | 85 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2013 | 448 | 0.130 |
Why?
|
| Transcriptome | 1 | 2019 | 387 | 0.120 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 540 | 0.110 |
Why?
|
| Regression Analysis | 2 | 2007 | 498 | 0.110 |
Why?
|
| Energy Metabolism | 1 | 2017 | 379 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 615 | 0.110 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 770 | 0.110 |
Why?
|
| Reimbursement, Incentive | 1 | 2013 | 29 | 0.100 |
Why?
|
| Multivariate Analysis | 2 | 2007 | 937 | 0.100 |
Why?
|
| Adult | 10 | 2020 | 16824 | 0.100 |
Why?
|
| Stereotaxic Techniques | 2 | 2007 | 29 | 0.100 |
Why?
|
| Membrane Proteins | 1 | 2019 | 895 | 0.100 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2013 | 31 | 0.100 |
Why?
|
| Exercise | 1 | 2020 | 942 | 0.100 |
Why?
|
| Parity | 1 | 2013 | 71 | 0.100 |
Why?
|
| Retrospective Studies | 2 | 2023 | 6658 | 0.100 |
Why?
|
| Gene Expression Regulation | 1 | 2019 | 1617 | 0.090 |
Why?
|
| Cell Lineage | 1 | 2013 | 270 | 0.090 |
Why?
|
| Risk Factors | 4 | 2020 | 5354 | 0.090 |
Why?
|
| Norovirus | 1 | 2011 | 6 | 0.090 |
Why?
|
| Virus Shedding | 1 | 2011 | 20 | 0.090 |
Why?
|
| Breast Diseases | 1 | 2011 | 40 | 0.090 |
Why?
|
| Societies, Medical | 1 | 2013 | 379 | 0.090 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2011 | 68 | 0.090 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2011 | 46 | 0.090 |
Why?
|
| HIV Seropositivity | 1 | 2011 | 84 | 0.090 |
Why?
|
| Stem Cells | 1 | 2013 | 259 | 0.090 |
Why?
|
| Diarrhea | 1 | 2011 | 76 | 0.090 |
Why?
|
| Disease Progression | 3 | 2023 | 1172 | 0.080 |
Why?
|
| Ultrasonography | 2 | 2003 | 484 | 0.080 |
Why?
|
| Aged | 7 | 2020 | 14447 | 0.080 |
Why?
|
| Quality Improvement | 1 | 2013 | 443 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 2 | 2020 | 456 | 0.070 |
Why?
|
| Therapeutic Touch | 1 | 2007 | 2 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 1553 | 0.060 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2005 | 8 | 0.060 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2005 | 16 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2005 | 33 | 0.060 |
Why?
|
| Pain Management | 1 | 2007 | 161 | 0.060 |
Why?
|
| United States | 2 | 2013 | 7843 | 0.060 |
Why?
|
| Pain | 1 | 2007 | 406 | 0.050 |
Why?
|
| Cyclohexanols | 1 | 2004 | 17 | 0.050 |
Why?
|
| Oxygen | 1 | 2005 | 317 | 0.050 |
Why?
|
| Aromatase Inhibitors | 1 | 2023 | 24 | 0.050 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2023 | 35 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2007 | 1256 | 0.050 |
Why?
|
| Perioperative Care | 1 | 2004 | 85 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2005 | 5462 | 0.050 |
Why?
|
| Neoplasm Staging | 1 | 2004 | 509 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2005 | 348 | 0.050 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2022 | 13 | 0.050 |
Why?
|
| Pain, Postoperative | 1 | 2004 | 162 | 0.050 |
Why?
|
| Estradiol | 1 | 2023 | 257 | 0.050 |
Why?
|
| Vacuum | 1 | 2002 | 7 | 0.050 |
Why?
|
| Dilatation, Pathologic | 1 | 2002 | 31 | 0.050 |
Why?
|
| Equipment Design | 1 | 2003 | 352 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2007 | 663 | 0.050 |
Why?
|
| Treatment Outcome | 4 | 2020 | 5680 | 0.040 |
Why?
|
| Glucose Tolerance Test | 1 | 2020 | 97 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2003 | 433 | 0.040 |
Why?
|
| Risk Reduction Behavior | 1 | 2020 | 121 | 0.040 |
Why?
|
| False Negative Reactions | 1 | 1999 | 41 | 0.040 |
Why?
|
| Histological Techniques | 1 | 1999 | 18 | 0.040 |
Why?
|
| Exercise Therapy | 1 | 2020 | 104 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 1999 | 78 | 0.040 |
Why?
|
| Cytodiagnosis | 1 | 1999 | 46 | 0.040 |
Why?
|
| Apoptosis | 2 | 2020 | 1079 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2019 | 88 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2007 | 2681 | 0.040 |
Why?
|
| Obesity | 1 | 2007 | 1235 | 0.040 |
Why?
|
| Gene Expression | 1 | 2022 | 840 | 0.040 |
Why?
|
| Calcinosis | 1 | 1999 | 85 | 0.040 |
Why?
|
| Young Adult | 2 | 2020 | 4694 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2003 | 1654 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2018 | 231 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 158 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2018 | 147 | 0.030 |
Why?
|
| Credentialing | 1 | 1997 | 15 | 0.030 |
Why?
|
| Pyruvic Acid | 1 | 2017 | 13 | 0.030 |
Why?
|
| Cell Respiration | 1 | 2017 | 21 | 0.030 |
Why?
|
| Metabolomics | 1 | 2017 | 52 | 0.030 |
Why?
|
| Ultrasonography, Interventional | 1 | 1997 | 107 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2017 | 326 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 1999 | 1147 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 1999 | 1094 | 0.030 |
Why?
|
| Data Collection | 1 | 1997 | 383 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2020 | 988 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 2018 | 295 | 0.030 |
Why?
|
| Prognosis | 1 | 2020 | 1748 | 0.030 |
Why?
|
| General Surgery | 1 | 1997 | 211 | 0.030 |
Why?
|
| Pain Measurement | 2 | 2007 | 345 | 0.030 |
Why?
|
| Massachusetts | 1 | 2020 | 2075 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2019 | 2109 | 0.030 |
Why?
|
| Biomarkers | 1 | 2019 | 1408 | 0.030 |
Why?
|
| Radiology | 1 | 1997 | 253 | 0.030 |
Why?
|
| Stomatitis | 1 | 2013 | 7 | 0.030 |
Why?
|
| Phenotype | 1 | 2017 | 1207 | 0.030 |
Why?
|
| Capecitabine | 1 | 2013 | 13 | 0.030 |
Why?
|
| Niacinamide | 1 | 2013 | 33 | 0.030 |
Why?
|
| Phenylurea Compounds | 1 | 2013 | 32 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2013 | 66 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2013 | 42 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 1 | 2013 | 56 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2013 | 59 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 242 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 298 | 0.020 |
Why?
|
| Fatigue | 1 | 2013 | 111 | 0.020 |
Why?
|
| Skin Diseases | 1 | 2013 | 82 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 2187 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 1997 | 712 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 422 | 0.020 |
Why?
|
| Gynecomastia | 1 | 2011 | 11 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2013 | 739 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 864 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2011 | 124 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2011 | 106 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2013 | 238 | 0.020 |
Why?
|
| Time Factors | 1 | 2017 | 3768 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2019 | 3035 | 0.020 |
Why?
|
| Adolescent | 1 | 2020 | 6245 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2011 | 378 | 0.020 |
Why?
|
| Comorbidity | 1 | 2011 | 1120 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2007 | 144 | 0.020 |
Why?
|
| Human papillomavirus 6 | 1 | 2005 | 4 | 0.020 |
Why?
|
| Cell Transformation, Viral | 1 | 2005 | 15 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2005 | 36 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2005 | 142 | 0.010 |
Why?
|
| Pregnancy | 1 | 2013 | 2334 | 0.010 |
Why?
|
| Mice | 1 | 2019 | 10844 | 0.010 |
Why?
|
| Oncogenes | 1 | 2005 | 68 | 0.010 |
Why?
|
| Venlafaxine Hydrochloride | 1 | 2004 | 15 | 0.010 |
Why?
|
| Anxiety | 1 | 2007 | 425 | 0.010 |
Why?
|
| Transfection | 1 | 2005 | 694 | 0.010 |
Why?
|
| Syndrome | 1 | 2004 | 180 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 896 | 0.010 |
Why?
|
| Analgesics | 1 | 2004 | 102 | 0.010 |
Why?
|
| Animals | 1 | 2019 | 20663 | 0.010 |
Why?
|
| Male | 2 | 2011 | 29891 | 0.010 |
Why?
|